Spectral Medical Inc
TSX:EDT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Spectral Medical Inc
Cash from Operating Activities
Spectral Medical Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Operating Activities
-CA$9.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-97%
|
CAGR 10-Years
0%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Cash from Operating Activities
-CA$8.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
$135.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash from Operating Activities
-$279.1m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-31%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Cash from Operating Activities
-CA$28.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-135%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Cash from Operating Activities
-$99.2m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Spectral Medical Inc
Glance View
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.
See Also
What is Spectral Medical Inc's Cash from Operating Activities?
Cash from Operating Activities
-9.5m
CAD
Based on the financial report for Dec 31, 2025, Spectral Medical Inc's Cash from Operating Activities amounts to -9.5m CAD.
What is Spectral Medical Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
0%
Over the last year, the Cash from Operating Activities growth was -8%. The average annual Cash from Operating Activities growth rates for Spectral Medical Inc have been 1% over the past three years , -97% over the past five years .
